Latest Headlines

31. Alveo Technologies Successfully Fulfills Expanded CDC Milestone Agreement To Advance Its Rapid Molecular Test For Both Seasonal And Avian Influenza A(H5) In Humans 8/26/2025

    Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary IntelliSense molecular detection technology, today announced that it has successfully fulfilled all objectives outlined in both its existing and follow-on expanded Agreement with the U.S Centers for Disease Control and Prevention (CDC) to further advance its rapid, molecular, point of care diagnostic, be.well to detect and differentiate between seasonal Influenzas A and B, as well as Influenza A(H5), a subtype of Influenza A commonly associated with Highly Pathogenic Avian Influenza, in humans.

32. AliveDx Registers MosaiQ®, Its Instrument For Multiplex Testing Of Autoimmune Diseases, Allergies And Beyond, As A Class II Exempt Device With The U.S. Food And Drug Administration (FDA) 8/26/2025

    AliveDx, the global in-vitro diagnostics company dedicated to advancing patient care, today announced that its MosaiQ® instrument is registered with the U.S. Food and Drug Administration (FDA) as a Class II 510(k) exempt medical device.

33. BillionToOne's Northstar Select® Demonstrates Superior Sensitivity In Prospective Head-To-Head Validation Study Publication 8/26/2025

    BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling1.

34. Deep Bio & Techcyte Partner To Integrate AI-Powered Prostate Diagnostics & Frozen Section On Techcyte Fusionx Platform 8/26/2025

    Deep Bio, a global leader in AI-powered cancer diagnostics, today announced a strategic partnership with Techcyte to integrate Deep Bio’s prostate and frozen section algorithm into the RUO Techcyte Fusion platform, which is CE marked in Europe and RUO in the US.

35. Corewell Health And Quest Diagnostics To Enter Into Joint Venture Providing Enhanced Laboratory Services In Michigan 8/26/2025

    Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

36. WMI Partners With Arcadea Group 8/26/2025

    Arcadea Group, a preeminent, long-term investor in global software businesses, today announced its acquisition of WMI, a leading provider of laboratory information management solutions in Brazil through its flagship Autolac software suite.

37. IPN Develops Innovative Rapid Test To Diagnose Childhood Leukemia 8/24/2025

    Researchers at the Instituto Politécnico Nacional (IPN) are developing a rapid test to detect childhood acute lymphoblastic leukemia, wto minimizethe use of invasive methods such as bone marrow biopsies and promote early diagnosis so that treatment can begin promptly.

38. New Sensor Is A Breath Of Fresh Air For Diagnosing Diabetes 8/22/2025

    In the U.S., one in five of the 37 million adults who has diabetes doesn’t know it. Current methods of diagnosing diabetes and prediabetes usually require a visit to a doctor’s office or lab work, both of which can be expensive and time-consuming.

39. Thermo Fisher Scientific Opens Manufacturing Center Of Excellence Site In North Carolina 8/21/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its innovative manufacturing center of excellence facility in Mebane, N.C.

40. DiamiR Biosciences And Aptorum Group Announce New York State Approval For DiamiR's APOE Genotyping Test 8/21/2025

    DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH).